title: Distribution of KRAS and BRAF mutations in Moroccan patients with advanced colorectal cancer.
abstract: Targeted therapies have an increasing importance in digestive oncology. To our knowledge, we are the first to report the distribution of KRAS and BRAF mutations in Moroccan patients with advanced colorectal cancer (CRC) in order to introduce targeted therapy in the arsenal of therapeutic modalities for management of this cancer in Morocco. In this study, 92 samples obtained from patients with CRC were tested for the presence of the nine most common mutations in the KRAS gene and BRAF gene. Among the tested patients, 76.09% of patients had wt-KRAS genotype and 23.91% were KRAS mutants and the majority of mutations would result in an amino acid substitution of glycine by aspartic acid (68.2%) The predominant mutations are G>A transitions and G>T transversions. Around 5% (5.43%) of the tested patients bore the V600E mutation in BRAF gene. Only one patient showing to have the V600E mutation in BRAF was also mutated-KRAS. Summing up the results about the KRAS and the BRAF mutation carriers from our study, the portion of potentially non responsive patients for the anti-EGFR treatment is 28.26%.
authors.affiliation: Laboratoire de génétique et biologie moléculaire, faculté des sciences Ben'Msik-Bd Driss Elharti, BP 79, 55, Sidi Othman, Casablanca, Morocco; Département de biologie moléculaire, centre spécialisé des analyses médicales Anoual-Casablanca, Casablanca, Morocco. Electronic address: mateux-tec@hotmail.fr.
authors.forename: N
authors.initials: N
authors.lastname: Marchoudi
authors.forename: H
authors.initials: H
authors.lastname: Amrani Hassani Joutei
authors.forename: F
authors.initials: F
authors.lastname: Jouali
authors.forename: J
authors.initials: J
authors.lastname: Fekkak
authors.forename: H
authors.initials: H
authors.lastname: Rhaissi
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D015179:Colorectal Neoplasms / Q000453:epidemiology / Q000235:genetics* / Q000473:pathology; D018450:Disease Progression; D019008:Drug Resistance, Neoplasm / Q000235:genetics; D066246:ErbB Receptors / Q000037:antagonists & inhibitors; D005260:Female; D005787:Gene Frequency; D006801:Humans; D008297:Male; D008875:Middle Aged; D009018:Morocco / Q000453:epidemiology; D009154:Mutation; D020641:Polymorphism, Single Nucleotide; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use; D011518:Proto-Oncogene Proteins / Q000235:genetics*; D048493:Proto-Oncogene Proteins B-raf / Q000235:genetics*; D016283:Proto-Oncogene Proteins p21(ras); D018631:ras Proteins / Q000235:genetics*
chemical_list: C117307:KRAS protein, human; D047428:Protein Kinase Inhibitors; D011518:Proto-Oncogene Proteins; C512478:EGFR protein, human; D066246:ErbB Receptors; C482119:BRAF protein, human; D048493:Proto-Oncogene Proteins B-raf; D016283:Proto-Oncogene Proteins p21(ras); D018631:ras Proteins
keywords: BRAF mutation; Cancer colorectal; Colorectal cancer; KRAS mutation; Mutation du BRAF; Mutation du KRAS